Genetic prognostic and predictive markers in colorectal cancer

2009 ◽  
Vol 9 (7) ◽  
pp. 489-499 ◽  
Author(s):  
Axel Walther ◽  
Elaine Johnstone ◽  
Charles Swanton ◽  
Rachel Midgley ◽  
Ian Tomlinson ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Predictive Markers ◽  
Prognostic And Predictive Markers

scholarly journals Role ofNRASmutations as prognostic and predictive markers in metastatic colorectal cancer

2014 ◽  
Vol 136 (1) ◽  
pp. 83-90 ◽  
Author(s):  
Marta Schirripa ◽  
Chiara Cremolini ◽  
Fotios Loupakis ◽  
Manfredi Morvillo ◽  
Francesca Bergamo ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Predictive Markers ◽  
Prognostic And Predictive Markers

scholarly journals Erratum: Genetic prognostic and predictive markers in colorectal cancer

2011 ◽  
Vol 11 (4) ◽  
pp. 309-309 ◽  
Author(s):  
Axel Walther ◽  
Elaine Johnstone ◽  
Charles Swanton ◽  
Rachel Midgley ◽  
Ian Tomlinson ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Predictive Markers ◽  
Prognostic And Predictive Markers

Role of Genomic Markers in Colorectal Cancer Treatment

2005 ◽  
Vol 23 (20) ◽  
pp. 4545-4552 ◽  
Author(s):  
Wendy L. Allen ◽  
Patrick G. Johnston
Keyword(s):  
Colorectal Cancer ◽  
Overall Survival ◽  
Drug Resistance ◽  
Response Rates ◽  
Predictive Markers ◽  
Genomic Markers ◽  
Resected Stage ◽  
Prognostic And Predictive Markers ◽  
Colorectal Cancer Treatment

For the last four decades, fluorouracil (FU) has been the main treatment of choice in colorectal cancer (CRC) in both the advanced and adjuvant settings. In the advanced setting, FU monotherapy produces response rates of only 10% to 20%. Furthermore, in resected stage III CRC, FU monotherapy has increased overall survival by only 20%. The combination of FU with newer therapies such as oxaliplatin and irinotecan has significantly improved response rates to 40% to 50%. Despite these improvements, more than half of advanced CRC patients derive no benefit from treatment; this is due to either acquired or inherent drug resistance. This review aims to highlight the current prognostic and predictive markers that have been identified for CRC to date. The limited use of these predictive markers underscores the importance of and need for multiple marker testing in order to improve response rates and decrease toxicity. This review will also focus on high throughput methods to identify panels of predictive markers for CRC, which ultimately aim to tailor treatment according to an individual patient and tumor profile.

scholarly journals Efficacy and safety of FOLFIRI/aflibercept in second‐line treatment of metastatic colorectal cancer in a real‐world population: Prognostic and predictive markers

2019 ◽  
Vol 8 (3) ◽  
pp. 882-889 ◽  
Author(s):  
Ana Fernández Montes ◽  
Nieves Martínez Lago ◽  
Marta Covela Rúa ◽  
Juan de la Cámara Gómez ◽  
Paula González Villaroel ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Real World ◽  
Predictive Markers ◽  
World Population ◽  
Line Treatment ◽  
Second Line ◽  
Efficacy And Safety ◽  
Prognostic And Predictive Markers

scholarly journals Exosomal microRNAs and other non-coding RNAs as colorectal cancer biomarkers: a review

Mutagenesis ◽  
2019 ◽  
Vol 35 (3) ◽  
pp. 243-260 ◽  
Author(s):  
Antonio Francavilla ◽  
Szimonetta Turoczi ◽  
Sonia Tarallo ◽  
Pavel Vodicka ◽  
Barbara Pardini ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Expression Profiles ◽  
Predictive Markers ◽  
Circular Rnas ◽  
Rna Molecules ◽  
Non Coding Rna ◽  
Non Coding Rnas ◽  
Prognostic And Predictive Markers

Abstract The circulating human transcriptome, which includes both coding and non-coding RNA (ncRNA) molecules, represents a rich source of potential biomarkers for colorectal cancer (CRC) that has only recently been explored. In particular, the release of RNA-containing extracellular vesicles (EVs), in a multitude of different in vitro cell systems and in a variety of body fluids, has attracted wide interest. The role of RNA species in EVs is still not fully understood, but their capacity to act as a form of distant communication between cells and their higher abundance in association with cancer demonstrated their relevance. In this review, we report the evidence from both in vitro and human studies on microRNAs (miRNAs) and other ncRNA profiles analysed in EVs in relation to CRC as diagnostic, prognostic and predictive markers. The studies so far highlighted that, in exosomes, the most studied category of EVs, several miRNAs are able to accurately discriminate CRC cases from controls as well as to describe the progression of the disease and its prognosis. Most of the time, the in vitro findings support the miRNA profiles detected in human exosomes. The expression profiles measured in exosomes and other EVs differ and, interestingly, there is a variability of expression also among different subsets of exosomes according to their proteic profile. On the other hand, evidence is still limited for what concerns exosome miRNAs as early diagnostic and predictive markers of treatment. Several other ncRNAs that are carried by exosomes, mostly long ncRNAs and circular RNAs, seem also to be dysregulated in CRC. Besides various technical challenges, such as the standardisation of EVs isolation methods and the optimisation of methodologies to characterise the whole spectrum of RNA molecules in exosomes, further studies are needed in order to elucidate their relevance as CRC markers.

Prognostic and Predictive Markers in Colorectal Cancer – The Role of New Genomic Technologies

2007 ◽  
Vol 5 (4) ◽  
pp. 255-261
Author(s):  
Vicky Coyle ◽  
Wendy Allen ◽  
Daniel Longley ◽  
Patrick Johnston
Keyword(s):  
Colorectal Cancer ◽  
Predictive Markers ◽  
Genomic Technologies ◽  
Prognostic And Predictive Markers
Sign in / Sign up

Export Citation Format

Share Document